Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.

Szczegóły
Comments

Tytuł:: Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
Autorzy:: El-Matary W; Department of Pediatrics, University of Manitoba, Winnipeg, MB, Canada.; IBD Clinical and Research Center, University of Manitoba, Winnipeg, MB, Canada.
Nugent Z; IBD Clinical and Research Center, University of Manitoba, Winnipeg, MB, Canada.; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Witt J; Department of Economics, University of Manitoba, Winnipeg, MB, Canada.
Bernstein CN; IBD Clinical and Research Center, University of Manitoba, Winnipeg, MB, Canada.; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Źródło:: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jun; Vol. 53 (11), pp. 1234-1235.
Typ publikacji:: Editorial; Comment
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
MeSH Terms:: Colitis*
Inflammatory Bowel Diseases*/epidemiology
Child ; Costs and Cost Analysis ; Humans
References:: El-Matary W, Nugent Z, Witt J, Bernstein CN. Trends in paediatric inflammatory bowel disease attributable direct costs: a population-based analysis. Aliment Pharmacol Ther. 2021;53:1201-1208.
Lachaine J, Feagan B, Martel MJ, Beauchemin C, McHugh K. The impact of TNF inhibitors for Crohn’s disease on health care resource utilization: an analysis using the RAMQ database. Value Health. 2012;15:A137.
Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in United States children and adults. Gastroenterology. 2008;135:1907-1913.
Vernon-Roberts A, Day AS. Editorial: trends in paediatric inflammatory bowel disease attributable direct costs. Aliment Pharmacol Ther. 2021;53:1232-1233.
Frei R, Fournier N, Zeitz J, et al. Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn's disease: 10-year-follow-up data from the Swiss IBD cohort study. J Crohns Colitis. 2019;13:1292-1301.
Carman N, Tomalty D, Church PC, et al. Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease. Gastrointest Endosc. 2019;89:364-372.
Walters TD, Kim M-O, Denson LA, et al.; PRO-KIIDS Research Group. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146:383-391.
El-Matary W, Leung S, Tennakoon A, et al. Trends of utilization of tumor necrosis factor antagonists in children with inflammatory bowel disease: a Canadian population-based study. Inflamm Bowel Dis. 2020;26:134-138.
Mulcahy AW, Predmore Z, Mattke S. The cost savings potential of biosimilar drugs in the United States [Internet]. Santa Monica (CA). Rand Corporation; 2014. [cited 2017 Jan 4]. http://www.rand.org/pubs/perspectives/PE127.html. Accessed October 26, 2020.
Entry Date(s):: Date Created: 20210507 Date Completed: 20210524 Latest Revision: 20210524
Update Code:: 20240104
DOI:: 10.1111/apt.16376
PMID:: 33961706
: Opinia redakcyjna

Pełny tekst

Comment on: Aliment Pharmacol Ther. 2021 Jun;53(11):1201-1208. (PMID: 33836105)
Comment on: Aliment Pharmacol Ther. 2021 Jun;53(11):1232-1233. (PMID: 33961703)

Informacja